260 related articles for article (PubMed ID: 34270461)
1. BMI1 activates P-glycoprotein via transcription repression of
Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
[TBL] [Abstract][Full Text] [Related]
2. MDR1 mediated chemoresistance: BMI1 and TIP60 in action.
Banerjee Mustafi S; Chakraborty PK; Naz S; Dwivedi SK; Street M; Basak R; Yang D; Ding K; Mukherjee P; Bhattacharya R
Biochim Biophys Acta; 2016 Aug; 1859(8):983-93. PubMed ID: 27295567
[TBL] [Abstract][Full Text] [Related]
3. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
Li Y; Zu X; Hu X; Wang L; He W
Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p.
Cheng FH; Zhao ZS; Liu WD
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7256-7265. PubMed ID: 31539112
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells.
Zhang S; Chang YY; Gong YW; Gao YJ; Guo Q; Wang YH; Zhao YL; Wang ZP
J Cell Biochem; 2019 Apr; 120(4):6347-6360. PubMed ID: 30304549
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
9. Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma.
Zhou Y; Zhang L; Pan H; Wang B; Yan F; Fang X; Munnee K; Tang Z
PLoS One; 2015; 10(4):e0123208. PubMed ID: 25915207
[TBL] [Abstract][Full Text] [Related]
10. MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH.
Wang Y; Dong L; Wan F; Chen F; Liu D; Chen D; Long J
Cell Death Dis; 2021 Sep; 12(10):861. PubMed ID: 34552061
[TBL] [Abstract][Full Text] [Related]
11. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
12. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Yin T; Zhang Z; Cao B; Duan Q; Shi P; Zhao H; Camara SN; Shen Q; Wang C
Oncotarget; 2016 Jun; 7(24):37192-37204. PubMed ID: 27177084
[TBL] [Abstract][Full Text] [Related]
13. PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
Tian R; Zhang C; Xiong F; Chen H
Front Biosci (Landmark Ed); 2020 Mar; 25(5):948-960. PubMed ID: 32114419
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
15. miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness.
Zhang Q; Zhuang J; Deng Y; Yang L; Cao W; Chen W; Lin T; Lv X; Yu H; Xue Y; Guo H
Theranostics; 2017; 7(19):4777-4790. PubMed ID: 29187903
[No Abstract] [Full Text] [Related]
16. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
Shen JG; Xu SN; Yin LG
Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
[TBL] [Abstract][Full Text] [Related]
17. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.
Xie X; Liu W; Duan Z; Li X; Zhang L; Yang G
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):143-148. PubMed ID: 32538761
[TBL] [Abstract][Full Text] [Related]
18. miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2.
Bao J; Xu Y; Wang Q; Zhang J; Li Z; Li D; Li J
Biomed Pharmacother; 2017 Aug; 92():1030-1037. PubMed ID: 28609840
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
[TBL] [Abstract][Full Text] [Related]
20. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
